Largomycin isolation

Process Developments in the Isolation of Largomycin F-II, a Chromoprotein Antitumor Antibiotic... 

Isolation of Largomycin F-II. Figure 3 graphically illustrates HPLC titers vs culture age for both cell free broth and mycelial extracts for a typical 14-liter and 300-liter fermentations. 

Prior to attempting any process development work, it was decided to evaluate the process reported by Yamaguchi et at (2) for the isolation of largomycin F-II. 

Figure 4. Non-chemical representation of the production and isolation of the chromoprotein antitumor antibiotic, largomycin F-Il. The person with a lighted lantern is the biologically active form of largomycin F-II.

NCI-FCRF Process II-B (Scheme 5). In this process the freeze-thaw step of mycelia suspension, to liberate largomycin F-II, of NCI-FCRF Process II-A has been replaced by vigorously mixing the mycelia suspension for 1 hour. The results of a 240 gallon fermentation run are summarized in Scheme 5. A comparison of the properties of the isolated product with the standard compound is shown in Table II, and their polyacrylamide gel electrophoresis pattern is shown in Figure 5. 

The other aspect of largomycin F-II purification that was routinely discussed within the Fermentation Program was whether it was better to isolate F-II from the supernatant or from the myce-... 

---